9 powodów, dla których warto wybrać furoinian mometazonu Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2015
Słowa kluczowe:
alergiczny nieżyt nosa, zapalenie błony śluzowej nosa i zatok przynosowych, leczenie, donosowe glikokortykosteroidy, furoinian mometazonu
##plugins.themes.bootstrap3.article.main##
Abstrakt
Donosowe glikokortykosteroidy (dnGKS) są obecnie najbardziej skutecznymi lekami w terapii alergicznych nieżytów nosa, ostrych nieżytów nosa, a także przewlekłych zapaleń zatok z polipami nosa i bez nich. Niewątpliwą zaletą donosowych glikokortykosteroidów jest ich silne, lokalne działanie przeciwzapalne przy minimalnym działaniu ogólnoustrojowym. Zgodnie z zaleceniami zawartymi w dokumentach PoSLeNN i ARIA 2010 w przypadku umiarkowanego i ciężkiego okresowego oraz każdego przewlekłego alergicznego nieżytu nosa lekiem pierwszego wyboru jest donosowy glikokortykosteroid. W artykule przedstawiono cechy wyróżniające furoinian mometazonu.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Rapiejko , P. (2015). 9 powodów, dla których warto wybrać furoinian mometazonu . Medycyna Faktów , 8(1(26), 50-55. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2324
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Brożek J.L., Bousquet J., Baena-Cagnani C.E. et al.: Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revison. J. Allergy Clin. Immunol. 2010; 126: 466-476.
2. Fokkens W.J., Lund V.J., Mullol J. et al.: EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50(1): 1-12.
3. Samoliński B., Arcimowicz M. (red.): Polskie Standardy Leczenia Nieżytów Nosa (PoSLeNN). Alergologia Polska 2013, S1.
4. Rapiejko P., Jurkiewicz D.: Donosowe glikokortykosteroidy w leczeniu nieżytów nosa. Terapia 2014; 22(10): 27-35.
5. Mygind N.: Local effect of intranasal beclomethasonedipropionate aerosol in hay fever. BMJ 1973; 4: 464-466.
6. Samoliński B., Nowicka A., Wojas O. et al.: Intranasal glucocorticosteroids – not only in allergic rhinitis In the 40th anniversary of intranasal glucocorticosteroids’ introduction. Otolaryngol Pol. 2014; 68(2): 51-64.
7. Meltzer E.O., Shekar T., Teper A.A.: Mometasone furoate nasal spray for moderate-to-severe nasal congestion in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2011; 32(2): 159-167.
8. Penagos M., Compalati E., Tarantini F. et al.: Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. Allergy 2008; 63(10): 1280-1291.
9. Small C.B., Hernandez J., Reyes A. et al.: Efficacy and safety of mometasone furoate nasal spray in nasal polyposis. J. Allergy Clin. Immunol. 2005; 116(6): 1275-1281.
10. Wei C.C., Kennedy D.W.: Mometasone implant for chronic rhinosinusitis. Med Devices (Auckl) 2012; 5: 75-80.
11. Svensson J., Lundberg J., Olsson P. et al.: Cost-effectiveness of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. Prim. Care Respir. J. 2012; 21(4): 412-418.
12. Rapiejko O.P., Zawisza E., Lipiec A. et al.: Wspomaganie antybiotykoterapii zapalenia zatok przynosowych glikokortykosteroidem prosluzanem mometazonu, stosowanym donosowo. Terapia 2001; 3.
13. Baena-Cagnani C.E., Patel P.: Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. Curr. Med. Res. Opin. 2010; 26: 2047-2055.
14. Baldwin C.M., Scott L.J.: Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs 2008; 68: 1723-1739.
15. Derendorf H., Meltzer E.O.: Molecular and clinical pharmacology of intranasal corticosteroid: clinical and therapeutic implications. Allergy 2008; 63: 1292-1300.
16. Sörensen H., Mygind N., Pedersen C.B. et al.: Long-term treatment of nasal polyps with beclomethasone dipropionate aerosol. III. Morphological studies and conclusions. Acta Otolaryngol. (Stockh) 1976; 82: 260-262.
17. Passalacqua G., Albano M., Canonica G.W. et al.: Inhaled and nasal corticosteroids: safety aspects. Allergy 2000; 55: 16-33.
18. Daley-Yates P.T., Kunka R.L., Yin Y. et al.: Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur. J. Clin. Pharmacol. 2004; 60(4): 265-268.
19. Schenkel E.J., Skoner D.P., Bronsky E.A. et al.: Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000; 105: e22.
20. Bruni F.M., De Luca G., Venturoli V. et al.: Intranasal corticosteroids and adrenal suppression. Neroimmunomodulation 2009; 16: 353-362.
21. Brannan M.D., Herron J.M., Affrime M.B.: Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin. Therapeutics. 1997; 19: 1330-1339.
22. Anolik R., Pearlman D., Teper A. et al.: Mometasone furoate improves nasal and ocular symptoms of seasonal allergic rhinitis in adolescents. Allergy Asthma Proc. 2009; 30: 406-412.
23. Ratner P.H., Meltzer E.O., Teper A.: Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. Int. J. Pediatr. Otorhinolaryngol. 2009; 73: 651-657.
24. Wandalsen G.F., Mendes A.I., Solé D.: Objective improvement in nasal congestion and nasal hyperreactivity with use of nasal steroids in persistent allergic rhinitis. Am. J. Rhinol. Allergy 2010; 24: e32-e36.
25. Minshall E., Ghaffar O., Cameron L. et al.: Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol. Head Neck Surg. 1998; 118: 648-654.
26. Sharpe S.A., Sandweiss V., Tuazon J. et al.: Comparison of the flow properties of aqueous suspension corticosteroid nasal sprays under differing sampling conditions. Drug Dev. Ind. Pharm. 2003; 29: 1005-1012.
27. Salapatek A.M., Patel P., Gopalan G. et al.: Mometasone furoate nasal spray provides early, continuing relief of nasal congestion and improves nasal patency in allergic patients. Am. J. Rhinol. Allergy 2010; 24: 433-438.
28. Charakterystyka Produktu Leczniczego. Nasometin.
29. Charakterystyka Produktu Leczniczego. Pronasal.
2. Fokkens W.J., Lund V.J., Mullol J. et al.: EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50(1): 1-12.
3. Samoliński B., Arcimowicz M. (red.): Polskie Standardy Leczenia Nieżytów Nosa (PoSLeNN). Alergologia Polska 2013, S1.
4. Rapiejko P., Jurkiewicz D.: Donosowe glikokortykosteroidy w leczeniu nieżytów nosa. Terapia 2014; 22(10): 27-35.
5. Mygind N.: Local effect of intranasal beclomethasonedipropionate aerosol in hay fever. BMJ 1973; 4: 464-466.
6. Samoliński B., Nowicka A., Wojas O. et al.: Intranasal glucocorticosteroids – not only in allergic rhinitis In the 40th anniversary of intranasal glucocorticosteroids’ introduction. Otolaryngol Pol. 2014; 68(2): 51-64.
7. Meltzer E.O., Shekar T., Teper A.A.: Mometasone furoate nasal spray for moderate-to-severe nasal congestion in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2011; 32(2): 159-167.
8. Penagos M., Compalati E., Tarantini F. et al.: Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. Allergy 2008; 63(10): 1280-1291.
9. Small C.B., Hernandez J., Reyes A. et al.: Efficacy and safety of mometasone furoate nasal spray in nasal polyposis. J. Allergy Clin. Immunol. 2005; 116(6): 1275-1281.
10. Wei C.C., Kennedy D.W.: Mometasone implant for chronic rhinosinusitis. Med Devices (Auckl) 2012; 5: 75-80.
11. Svensson J., Lundberg J., Olsson P. et al.: Cost-effectiveness of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. Prim. Care Respir. J. 2012; 21(4): 412-418.
12. Rapiejko O.P., Zawisza E., Lipiec A. et al.: Wspomaganie antybiotykoterapii zapalenia zatok przynosowych glikokortykosteroidem prosluzanem mometazonu, stosowanym donosowo. Terapia 2001; 3.
13. Baena-Cagnani C.E., Patel P.: Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. Curr. Med. Res. Opin. 2010; 26: 2047-2055.
14. Baldwin C.M., Scott L.J.: Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs 2008; 68: 1723-1739.
15. Derendorf H., Meltzer E.O.: Molecular and clinical pharmacology of intranasal corticosteroid: clinical and therapeutic implications. Allergy 2008; 63: 1292-1300.
16. Sörensen H., Mygind N., Pedersen C.B. et al.: Long-term treatment of nasal polyps with beclomethasone dipropionate aerosol. III. Morphological studies and conclusions. Acta Otolaryngol. (Stockh) 1976; 82: 260-262.
17. Passalacqua G., Albano M., Canonica G.W. et al.: Inhaled and nasal corticosteroids: safety aspects. Allergy 2000; 55: 16-33.
18. Daley-Yates P.T., Kunka R.L., Yin Y. et al.: Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur. J. Clin. Pharmacol. 2004; 60(4): 265-268.
19. Schenkel E.J., Skoner D.P., Bronsky E.A. et al.: Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000; 105: e22.
20. Bruni F.M., De Luca G., Venturoli V. et al.: Intranasal corticosteroids and adrenal suppression. Neroimmunomodulation 2009; 16: 353-362.
21. Brannan M.D., Herron J.M., Affrime M.B.: Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin. Therapeutics. 1997; 19: 1330-1339.
22. Anolik R., Pearlman D., Teper A. et al.: Mometasone furoate improves nasal and ocular symptoms of seasonal allergic rhinitis in adolescents. Allergy Asthma Proc. 2009; 30: 406-412.
23. Ratner P.H., Meltzer E.O., Teper A.: Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. Int. J. Pediatr. Otorhinolaryngol. 2009; 73: 651-657.
24. Wandalsen G.F., Mendes A.I., Solé D.: Objective improvement in nasal congestion and nasal hyperreactivity with use of nasal steroids in persistent allergic rhinitis. Am. J. Rhinol. Allergy 2010; 24: e32-e36.
25. Minshall E., Ghaffar O., Cameron L. et al.: Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol. Head Neck Surg. 1998; 118: 648-654.
26. Sharpe S.A., Sandweiss V., Tuazon J. et al.: Comparison of the flow properties of aqueous suspension corticosteroid nasal sprays under differing sampling conditions. Drug Dev. Ind. Pharm. 2003; 29: 1005-1012.
27. Salapatek A.M., Patel P., Gopalan G. et al.: Mometasone furoate nasal spray provides early, continuing relief of nasal congestion and improves nasal patency in allergic patients. Am. J. Rhinol. Allergy 2010; 24: 433-438.
28. Charakterystyka Produktu Leczniczego. Nasometin.
29. Charakterystyka Produktu Leczniczego. Pronasal.